Search

Congcong M Sun

from Cupertino, CA
Age ~52
Get Report
Also known as:
Cong Cong Sun, Megan Sun, Sun Congcong
Phone and address:
18785 Tilson Ave, Cupertino, CA 95014
Related to:
Yong Sun, 49Wei C Lee, 47Young K SunYoung Kim, 63Sung Kim, 65
Connected to:
A Sun, 59Able M Sun, 60Alisa Sun, 32Amie Y Sun, 37Angela C Sun, 37Ari Sun, 51Bao H Sun, 53Belle D Sun, 59Ben C Sun, 68Bessie W Sun, 73

Congcong Sun Phones & Addresses

  • 18785 Tilson Ave, Cupertino, CA 95014
  • Albany, OR
  • Corvallis, OR
  • 926 Woodside Rd, Redwood City, CA 94061 (650) 839-1874
  • Sunnyvale, CA
  • Mountain View, CA
  • La Jolla, CA
  • San Francisco, CA
  • San Diego, CA
  • 926 Woodside Rd, Redwood City, CA 94061

Emails

m***[email protected]

Publications

Us Patents

Compounds For Enzyme Inhibition

View page
US Patent:
20070105786, May 10, 2007
Filed:
Nov 9, 2006
Appl. No.:
11/595804
Inventors:
Han-Jie Zhou - Foster City CA, US
Congcong Sun - Cupertino CA, US
Kevin Shenk - Palo Alto CA, US
Guy Laidig - Menlo Park CA, US
Assignee:
Proteolix, Inc. - South San Francisco CA
International Classification:
A61K 38/04
C07K 5/06
US Classification:
514019000, 548954000, 549090000, 549551000
Abstract:
Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profiles

Compounds For Enzyme Inhibition

View page
US Patent:
20090203698, Aug 13, 2009
Filed:
Nov 9, 2006
Appl. No.:
12/084838
Inventors:
Han-Jie Zhou - Foster City CA, US
Congcong M. Sun - Cupertino CA, US
Kevin D. Shenk - Palo Alto CA, US
Guy J. Laidjg - Menlo Park CA, US
Assignee:
PROTEOLIX, INC. - South San Francisco CA
International Classification:
A61K 31/422
C07D 413/12
C07D 413/14
A61K 31/5377
A61P 37/00
A61P 31/00
A61P 35/00
A61P 21/00
A61P 31/18
A61P 29/00
US Classification:
5142368, 548248, 544137, 514378
Abstract:
Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profiles.

Compounds For Enzyme Inhibition

View page
US Patent:
20130130968, May 23, 2013
Filed:
Jan 8, 2013
Appl. No.:
13/736605
Inventors:
Onyx Therapeutics - South San Francisco CA, US
Congcong M. Sun - Cupertino CA, US
Kevin D. Shenk - Palo Alto CA, US
Guy J. Laidig - Menlo Park CA, US
Assignee:
ONYX THERAPEUTICS, INC. - South San Francisco CA
International Classification:
C07K 5/083
A61K 38/06
A61K 31/69
C07K 5/097
US Classification:
514 17, 514 201
Abstract:
Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profiles.

Compounds For Enzyme Inhibition

View page
US Patent:
20140031297, Jan 30, 2014
Filed:
Sep 26, 2013
Appl. No.:
14/038515
Inventors:
Congcong M. Sun - Cupertino CA, US
Kevin D. Shenk - Palo Alto CA, US
Guy J. Laidig - Menlo Park CA, US
Assignee:
Onyx Therapeutics, Inc. - South San Francisco CA
International Classification:
C07K 5/083
C07K 5/097
US Classification:
514 201
Abstract:
Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profiles.

Compounds For Enzyme Inhibition

View page
US Patent:
20140050737, Feb 20, 2014
Filed:
Sep 26, 2013
Appl. No.:
14/038626
Inventors:
Congcong M. Sun - Cupertino CA, US
Kevin D. Shenk - Palo Alto CA, US
Guy J. Laidig - Menlo Park CA, US
Assignee:
Onyx Therapeutics, Inc. - South San Francisco CA
International Classification:
A61K 38/06
A61K 45/06
US Classification:
4241411, 514 193
Abstract:
Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profiles.

Compounds For Enzyme Inhibition

View page
US Patent:
20140051641, Feb 20, 2014
Filed:
Sep 26, 2013
Appl. No.:
14/038591
Inventors:
Congcong M. Sun - Cupertino CA, US
Kevin D. Shenk - Palo Alto CA, US
Guy J. Laidig - Menlo Park CA, US
Assignee:
Onyx Therapeutics, Inc. - South San Francisco CA
International Classification:
A61K 38/06
A61K 45/06
US Classification:
514 193
Abstract:
Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profiles.

Compunds For Enzyme Inhibition

View page
US Patent:
20170260230, Sep 14, 2017
Filed:
May 26, 2017
Appl. No.:
15/606076
Inventors:
- Thousand Oaks CA, US
Congcong M. Sun - Cupertino CA, US
Kevin D. Shenk - Palo Alto CA, US
Guy J. Laidig - Menlo Park CA, US
International Classification:
C07K 5/08
C07K 5/062
C07K 5/065
C07K 5/078
A61K 38/06
C07K 5/087
C07K 5/097
C07K 5/117
A61K 31/69
A61K 38/55
C07K 5/083
Abstract:
Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profiles.

Compunds For Enzyme Inhibition

View page
US Patent:
20160083421, Mar 24, 2016
Filed:
Dec 7, 2015
Appl. No.:
14/960957
Inventors:
- South San Francisco CA, US
Congcong M. Sun - Cupertino CA, US
Kevin D. Shenk - Palo Alto CA, US
Guy J. Laidig - Menlo Park CA, US
International Classification:
C07K 5/08
Abstract:
Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profiles.
Control profile
Congcong M Sun from Cupertino, CA, age ~52 Get Report